Novo’s Drug Ingredient Could Do More Than Weight Loss:
Novo Nordisk is advancing its obesity-focused programs, with mid-stage signals that the main ingredient in Ozempic and Wegovy may influence glucose regulation beyond weight…
Novo Nordisk is advancing its obesity-focused programs, with mid-stage signals that the main ingredient in Ozempic and Wegovy may influence glucose regulation beyond weight…
Eli Lilly and Novo Nordisk are expanding production capacity for obesity and weight-loss treatments to support anticipated growth as medical coverage broadens and demand…
The leadership change at Novo Nordisk reflects its commitment to securing Novo US market leadership amid increasing competition and pricing pressures in the
The Metsera stock decline reflects investor concerns following Novo Nordisk's withdrawal from the bidding process, impacting the company's valuation and market
SoftBank Marvell Pfizer Novo reflect ongoing strategic moves in the technology and healthcare sectors, with SoftBank exploring semiconductor investments and
Novo Nordisk announced plans to reduce its workforce by approximately 11%, as part of a broader strategy to accelerate its efforts in the obesity…